“Werewolf continues to advance our conditionally activated INDUKINE™ therapies into clinical development,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf. “Most notably, we received FDA clearance to launch our first-in-human study ...
“At SITC, we look forward to sharing first-in-human clinical results from our lead candidate, WTX-124, including initial assessments of safety, pharmacokinetics, relevant biomarkers and preliminary antitumor activity from the ongoing monotherapy dose-escalation portion of our Phase 1/1b...
WTX-124是白介素-2(IL-2)INDUKINE分子,用于治疗晚期实体瘤,被设计为在肿瘤中激活后,保持对受体IL-2Ra/ß/g的高亲和力。该管线预计在2022年上半年提交IND。 WTX-330是白介素-12(IL12)的INDUKINE分子,主要在外周不与正常组织的IL-12受体的相互作用,以限制全身毒性,在肿瘤中有条件激活。预计在2022年上半年...
WTX-124:a systemically delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE molecule being developed as monotherapy and in combination with checkpoint inhibitor therapy in multiple solid tumor types. Werewolf is progressing Study WTX-124x2101, its Phase 1/1b, mult...
WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent ...
WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with pembrolizumab in multiple solid tumor types. WTX-330 is in developmen...
公司基于PREDATOR技术平台开发了三条候选产品管线:WTX-124、WTX-330和WTX-613,用于治疗复发性或难治性晚期实体瘤、淋巴瘤、血液恶性肿瘤等。除此之外,公司还在开展其他肿瘤免疫学计划,将新型工程方法应用于其他目标。公司预计在2022年上半年为WTX-124、WTX-330提交临床研究申请(IND),在2023年上半年为WTX-613提交临床...
根据该协议,Jazz 将获得Werewolf研究药物 WTX-613 的独家全球开发和商业化权利,这是一种差异化的、有条件激活的干扰素 α (IFNα)分子。根据交易条款,Jazz 将向 Werewolf 支付1500万美元的预付款,Werewolf 有资格获得高达12.6 亿美元的开发、监管和商业里程碑付款,以及产品销售的特许权使用费。
WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to adv...
WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in ...